tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
The FlyWedbush sees no threat to Ascendis’ Yorvipath from competitor data
4d ago
MBX
ASND
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
PremiumRatings
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
4d ago
ASND
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
PremiumRatings
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
4d ago
ASND
MBX Biosciences price target raised to $80 from $38 at Oppenheimer
PremiumThe Fly
MBX Biosciences price target raised to $80 from $38 at Oppenheimer
4d ago
MBX
ASND
Yun Zhong Reaffirms Buy Rating for Ascendis Pharma Amidst Competitive Uncertainties
PremiumRatings
Yun Zhong Reaffirms Buy Rating for Ascendis Pharma Amidst Competitive Uncertainties
4d ago
ASND
Ascendis Pharma Grants Employee Warrants to Boost Engagement
PremiumCompany AnnouncementsAscendis Pharma Grants Employee Warrants to Boost Engagement
16d ago
6K
ASND
Ascendis Pharma price target raised to $230 from $227 at BofA
Premium
The Fly
Ascendis Pharma price target raised to $230 from $227 at BofA
25d ago
ASND
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
Premium
Ratings
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
25d ago
ASND
Ascendis Pharma price target raised to $260 from $254 at JPMorgan
PremiumThe Fly
Ascendis Pharma price target raised to $260 from $254 at JPMorgan
1M ago
ASND
Ascendis Pharma Grants Employee Warrants to Foster Growth
PremiumCompany Announcements
Ascendis Pharma Grants Employee Warrants to Foster Growth
1M ago
6K
ASND
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
PremiumCompany Announcements
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
1M ago
ASND
UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
PremiumMarket News
UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
2M ago
ABT
DHR
Ascendis Pharma price target raised to $227 from $194 at TD Cowen
PremiumThe FlyAscendis Pharma price target raised to $227 from $194 at TD Cowen
2M ago
ASND
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
Premium
The Fly
Ascendis Pharma price target raised to $230 from $210 at RBC Capital
2M ago
ASND
Ascendis Pharma price target raised to $307 from $306 at UBS
Premium
The Fly
Ascendis Pharma price target raised to $307 from $306 at UBS
2M ago
ASND
Ascendis Pharma price target raised to $290 from $243 at Citi
PremiumThe Fly
Ascendis Pharma price target raised to $290 from $243 at Citi
2M ago
ASND
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
PremiumThe Fly
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
2M ago
ASND
Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
PremiumRatings
Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
2M ago
ASND
Ascendis Pharma Reports Strong Q2 2025 Growth
PremiumCompany Announcements
Ascendis Pharma Reports Strong Q2 2025 Growth
2M ago
ASND
Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
PremiumRatingsAscendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
2M ago
ASND
Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
Premium
Company Announcements
Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
2M ago
6K
ASND
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
Premium
The Fly
Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year
2M ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >